Compare Enveric Biosciences Inc (ENVB) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs IAC/Interactivecorp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while IAC/Interactivecorp trades at $40.86 (market cap $3.05B). The key difference: IAC/Interactivecorp is far larger — about 448.5× Enveric Biosciences Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and IAC/Interactivecorp for 79 Days on average.
| ENVB | PPLI | |
|---|---|---|
Market Cap | $6.80M | $3.05B |
Volume | 64,867 | 931,019 |
Sector | Health | Media |
52-Week High | $10.80 | $47.62 |
52-Week Low | $1.27 | $31.52 |
Typical Hold Time | 14 Days | 79 Days |
Enterprise Value | -$1.49M | $3.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
PPLI trades at $40.94, up 0.86% with bullish technical signals and strong analyst support (71% buy ratings). The stock shows mixed fundamentals with a low P/E of 6.92 and P/B of 0.6, but recent earnings volatility includes two misses and one beat. Recent MGM takeover speculation has driven significant price movement, with shares surging 11.3% following acquisition discussions.
Investment outlook balances attractive valuation metrics against operational challenges. The company faces revenue decline from $5.2B (2022) to $2.4B (2025) and negative net income in 2025, though 2026 projections show recovery. Key risks include media industry headwinds and execution uncertainty, while MGM deal potential offers upside catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
